EP4132569A4 - Anti-phf-tau antibodies and uses thereof - Google Patents

Anti-phf-tau antibodies and uses thereof

Info

Publication number
EP4132569A4
EP4132569A4 EP21783771.5A EP21783771A EP4132569A4 EP 4132569 A4 EP4132569 A4 EP 4132569A4 EP 21783771 A EP21783771 A EP 21783771A EP 4132569 A4 EP4132569 A4 EP 4132569A4
Authority
EP
European Patent Office
Prior art keywords
phf
tau antibodies
tau
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21783771.5A
Other languages
German (de)
French (fr)
Other versions
EP4132569A1 (en
Inventor
Kolen Kristof Van
Marc Mercken
Rupesh Nanjunda
Sanjaya Singh
Porte Sherry La
Jinquan Luo
Pharavee Jaiprasart
Sathyadevi Venkataramani
Rajkumar Ganesan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of EP4132569A1 publication Critical patent/EP4132569A1/en
Publication of EP4132569A4 publication Critical patent/EP4132569A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
EP21783771.5A 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof Pending EP4132569A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (2)

Publication Number Publication Date
EP4132569A1 EP4132569A1 (en) 2023-02-15
EP4132569A4 true EP4132569A4 (en) 2024-07-31

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21783771.5A Pending EP4132569A4 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Country Status (18)

Country Link
US (1) US20230151083A1 (en)
EP (1) EP4132569A4 (en)
JP (1) JP2023521763A (en)
KR (1) KR20220166308A (en)
CN (1) CN115697393A (en)
AU (1) AU2021251486A1 (en)
BR (1) BR112022020410A2 (en)
CA (1) CA3179914A1 (en)
CL (1) CL2022002766A1 (en)
CO (1) CO2022015737A2 (en)
CR (1) CR20220505A (en)
DO (1) DOP2022000218A (en)
EC (1) ECSP22078815A (en)
IL (1) IL297231A (en)
MX (1) MX2022012628A (en)
PE (1) PE20230385A1 (en)
TW (1) TW202204402A (en)
WO (1) WO2021205359A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202345899A (en) * 2022-03-11 2023-12-01 比利時商健生藥品公司 Multispecific antibodies and uses thereof
WO2023170290A1 (en) * 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
CN106939047B (en) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
JOP20180021A1 (en) * 2017-03-16 2019-01-30 Janssen Biotech Inc Anti-phf-tau antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096380A2 (en) * 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021205359A1 *
VANDERMEEREN MARC ET AL: "Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo", JOURNAL OF ALZHEIMER`S DISEASE, vol. 65, no. 1, 7 August 2018 (2018-08-07), NL, pages 265 - 281, XP055860147, ISSN: 1387-2877, Retrieved from the Internet <URL:http://dx.doi.org/10.3233/JAD-180404> DOI: 10.3233/JAD-180404 *

Also Published As

Publication number Publication date
MX2022012628A (en) 2023-01-11
EP4132569A1 (en) 2023-02-15
IL297231A (en) 2022-12-01
CL2022002766A1 (en) 2023-04-21
AU2021251486A1 (en) 2022-12-08
DOP2022000218A (en) 2023-04-30
TW202204402A (en) 2022-02-01
CN115697393A (en) 2023-02-03
CR20220505A (en) 2023-05-31
CA3179914A1 (en) 2021-10-14
BR112022020410A2 (en) 2023-01-03
PE20230385A1 (en) 2023-03-06
ECSP22078815A (en) 2022-11-30
KR20220166308A (en) 2022-12-16
JP2023521763A (en) 2023-05-25
CO2022015737A2 (en) 2023-02-27
US20230151083A1 (en) 2023-05-18
WO2021205359A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
EP4141029A4 (en) Antibody against nectin-4 and application thereof
GB202017058D0 (en) Antibodies and uses thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
EP4146272A4 (en) Covid-19 antibodies and uses thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
EP4169948A4 (en) Anti-cd73 antibody and use thereof
EP4141030A4 (en) Anti-cd73 antibody and use thereof
IL308808A (en) Anti-ccr8 antibodies and uses thereof
EP4132569A4 (en) Anti-phf-tau antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL289656A (en) Anti-tigit antibodies and application thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL307267A (en) Anti-cd122 antibodies and uses thereof
IL308382A (en) Novel anti-cd276 antibodies and the uses thereof
IL291550A (en) Anti-il-27 antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
EP4163300A4 (en) Gfral-antagonistic antibody and use thereof
IL304412A (en) Antibodies against cd112r and uses thereof
IL308198A (en) Anti-il-27 antibodies and uses thereof
IL307940A (en) Anti-adgre2 antibodies and uses thereof
EP4339208A4 (en) Anti-tigit antibodies and use thereof
IL288807A (en) Anti-talen antibodies and uses thereof
EP4299590A4 (en) Anti-siglec15 antibody and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20240402BHEP

Ipc: A61K 39/395 20060101ALI20240402BHEP

Ipc: A61K 39/00 20060101AFI20240402BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20240701

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20240625BHEP

Ipc: A61K 39/395 20060101ALI20240625BHEP

Ipc: A61K 39/00 20060101AFI20240625BHEP